Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Trial of Praziquantel Orodispersible Tablet in Schistosoma-Infected Preschool-Age Children

Trial Profile

A Phase III Trial of Praziquantel Orodispersible Tablet in Schistosoma-Infected Preschool-Age Children

Planning
Phase of Trial: Phase III

Latest Information Update: 29 May 2018

At a glance

  • Drugs Praziquantel (Primary)
  • Indications Schistosomiasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 29 May 2018 New trial record
    • 22 May 2018 According to a Pediatric Praziquantel Consortium media release, the consortium aims to submit a Marketing Authorization Application in 2020, and to have the product (orodispersible praziquantel tablet) available in 2021, for launch in the first endemic countries in Africa.
    • 22 May 2018 According to a Pediatric Praziquantel Consortium media release, this trial is a part of a phase III program.The phase III program is co-funded by the Pediatric Praziquantel Consortium, the European & Developing Countries Clinical Trials Partnership and the Global Health Innovative Technology Fund.Merck KGaA leads this phase III program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top